Literature DB >> 26585423

Vitamin D represses rhinovirus replication in cystic fibrosis cells by inducing LL-37.

Aline Schögler1, Ricardo J Muster2, Elisabeth Kieninger3, Carmen Casaulta4, Caroline Tapparel5, Andreas Jung6, Alexander Moeller6, Thomas Geiser7, Nicolas Regamey8, Marco P Alves9.   

Abstract

Vitamin D has immunomodulatory properties in the defence against pathogens. Its insufficiency is a widespread feature of cystic fibrosis (CF) patients, which are repeatedly suffering from rhinovirus (RV)-induced pulmonary exacerbations.To investigate whether vitamin D has antiviral activity, primary bronchial epithelial cells from CF children were pre-treated with vitamin D and infected with RV16. Antiviral and anti-inflammatory activity of vitamin D was assessed. RV and LL-37 levels were measured in bronchoalveolar lavage (BAL) of CF children infected with RV.Vitamin D reduced RV16 load in a dose-dependent manner in CF cells (10(-7 )M, p<0.01). The antiviral response mediated by interferons remained unchanged by vitamin D in CF cells. Vitamin D did not exert anti-inflammatory properties in RV-infected CF cells. Vitamin D increased the expression of the antimicrobial peptide LL-37 up to 17.4-fold (p<0.05). Addition of exogenous LL-37 decreased viral replication by 4.4-fold in CF cells (p<0.05). An inverse correlation between viral load and LL-37 levels in CF BAL (r=-0.48, p<0.05) was observed.RV replication in primary CF bronchial cells was reduced by vitamin D through the induction of LL-37. Clinical studies are needed to determine the importance of an adequate control of vitamin D for prevention of virus-induced pulmonary CF exacerbations.
Copyright ©ERS 2016.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 26585423     DOI: 10.1183/13993003.00665-2015

Source DB:  PubMed          Journal:  Eur Respir J        ISSN: 0903-1936            Impact factor:   16.671


  36 in total

1.  Vitamin D treatment modulates immune activation in cystic fibrosis.

Authors:  T Pincikova; D Paquin-Proulx; J K Sandberg; M Flodström-Tullberg; L Hjelte
Journal:  Clin Exp Immunol       Date:  2017-05-24       Impact factor: 4.330

Review 2.  Antimicrobial host defence peptides: functions and clinical potential.

Authors:  Neeloffer Mookherjee; Marilyn A Anderson; Henk P Haagsman; Donald J Davidson
Journal:  Nat Rev Drug Discov       Date:  2020-02-27       Impact factor: 84.694

3.  Lung allograft donors with excessive alcohol use have increased levels of human antimicrobial peptide LL-37.

Authors:  M Camargo Moreno; J B Lewis; E J Kovacs; E M Lowery
Journal:  Alcohol       Date:  2018-11-09       Impact factor: 2.405

4.  Vitamin D for the Immune System in Cystic Fibrosis (DISC): a double-blind, multicenter, randomized, placebo-controlled clinical trial.

Authors:  Vin Tangpricha; Joshua Lukemire; Yuqing Chen; José Nilo G Binongo; Suzanne E Judd; Ellen S Michalski; Moon J Lee; Seth Walker; Thomas R Ziegler; Rabin Tirouvanziam; Susu M Zughaier; Supavit Chesdachai; Wendy A Hermes; James F Chmiel; Ruth E Grossmann; Amit Gaggar; Patricia M Joseph; Jessica A Alvarez
Journal:  Am J Clin Nutr       Date:  2019-03-01       Impact factor: 7.045

5.  LL-37 disrupts the Kaposi's sarcoma-associated herpesvirus envelope and inhibits infection in oral epithelial cells.

Authors:  David C Brice; Zsolt Toth; Gill Diamond
Journal:  Antiviral Res       Date:  2018-08-02       Impact factor: 5.970

6.  Serum LL-37 Levels Associated With Severity of Bronchiolitis and Viral Etiology.

Authors:  Jonathan M Mansbach; Kohei Hasegawa; Nadim J Ajami; Joseph F Petrosino; Pedro A Piedra; Courtney N Tierney; Janice A Espinola; Carlos A Camargo
Journal:  Clin Infect Dis       Date:  2017-09-15       Impact factor: 9.079

Review 7.  Antiviral Activities of Human Host Defense Peptides.

Authors:  David C Brice; Gill Diamond
Journal:  Curr Med Chem       Date:  2020       Impact factor: 4.530

Review 8.  Experimental Antiviral Therapeutic Studies for Human Rhinovirus Infections.

Authors:  James A Coultas; John Cafferkey; Patrick Mallia; Sebastian L Johnston
Journal:  J Exp Pharmacol       Date:  2021-07-09

9.  Abnormal vitamin D and lipid profile in HTLV-1-associated myelopathy/tropical spastic paraparesis (HAM/TSP) patients.

Authors:  Reza Derakhshan; Ali Mirhosseini; Sanaz Ahmadi Ghezeldasht; Hamid Reza Jahantigh; Mehran Mohareri; Reza Boostani; Mohammad Derakhshan; Seyed Abdolrahim Rezaee
Journal:  Mol Biol Rep       Date:  2019-11-11       Impact factor: 2.742

Review 10.  Vitamin D-Regulated MicroRNAs: Are They Protective Factors against Dengue Virus Infection?

Authors:  John F Arboleda; Silvio Urcuqui-Inchima
Journal:  Adv Virol       Date:  2016-05-11
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.